;PMID: 8101511
;source_file_2966.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..40] = [t:0..40]
;1)sentence:[e:46..119] = [t:46..119]
;2)section:[e:123..145] = [t:123..145]
;3)section:[e:149..244] = [t:149..244]
;4)sentence:[e:248..448] = [t:248..448]
;5)sentence:[e:449..762] = [t:449..762]
;6)sentence:[e:763..850] = [t:763..850]
;7)sentence:[e:851..1118] = [t:851..1118]
;8)sentence:[e:1119..1276] = [t:1119..1276]
;9)sentence:[e:1277..1482] = [t:1277..1482]
;10)section:[e:1486..1530] = [t:1486..1530]

;section 0 Span:0..40
;Int J Cancer.  1993 Jul 30;54(6):987-91.
(SEC
  (FRAG (NNP:[0..3] Int) (NNP:[4..5] J) (NNP:[6..12] Cancer) (.:[12..13] .)
        (CD:[15..19] 1993) (NNP:[20..23] Jul) (CD:[24..26] 30) (CD:[26..29] ;54)
        (-LRB-:[29..30] -LRB-) (CD:[30..31] 6) (-RRB-:[31..32] -RRB-)
        (CD:[32..36] :987) (::[36..37] -) (CD:[37..39] 91) (.:[39..40] .)))

;sentence 1 Span:46..119
;Activation of the human MDR1 gene promoter in differentiated neuroblasts.
;[70..74]:gene-rna:"MDR1"
(SENT
  (NP-HLN
    (NP (NN:[46..56] Activation))
    (PP (IN:[57..59] of)
      (NP (DT:[60..63] the) (JJ:[64..69] human)
        (NML (NN:[70..74] MDR1) (NN:[75..79] gene))
        (NN:[80..88] promoter)))
    (PP-LOC (IN:[89..91] in)
      (NP (VBN:[92..106] differentiated) (NNS:[107..118] neuroblasts)))
    (.:[118..119] .)))

;section 2 Span:123..145
;Ferrandis E, Benard J.
(SEC
  (FRAG (NNP:[123..132] Ferrandis) (NNP:[133..134] E) (,:[134..135] ,)
        (NNP:[136..142] Benard) (NNP:[143..145] J.)))

;section 3 Span:149..244
;Laboratory of Clinical and Molecular Pharmacology, Institut Gustave Roussy, 
;Villejuif, France.
(SEC
  (FRAG (NNP:[149..159] Laboratory) (IN:[160..162] of) (NNP:[163..171] Clinical)
        (CC:[172..175] and) (NNP:[176..185] Molecular)
        (NNP:[186..198] Pharmacology) (,:[198..199] ,) (NNP:[200..208] Institut)
        (NNP:[209..216] Gustave) (NNP:[217..223] Roussy) (,:[223..224] ,)
        (NNP:[226..235] Villejuif) (,:[235..236] ,) (NNP:[237..243] France)
        (.:[243..244] .)))

;sentence 4 Span:248..448
;When treated in vitro with retinoic acid, many neuroblastoma cell lines
;undergo  neuronal differentiation and show a significant increase in human
;multi-drug  resistance gene (MDRI) transcript levels.
;[295..308]:malignancy-type:"neuroblastoma"
;[395..422]:gene-rna:"multi-drug  resistance gene"
;[424..428]:gene-rna:"MDRI"
(SENT
  (S
    (SBAR-ADV
      (WHADVP-1 (WRB:[248..252] When))
      (S
        (NP-SBJ-2 (-NONE-:[252..252] *))
        (VP (VBN:[253..260] treated)
          (NP-2 (-NONE-:[260..260] *))
          (ADVP (FW:[261..263] in) (FW:[264..269] vitro))
          (PP-MNR (IN:[270..274] with)
            (NP (JJ:[275..283] retinoic) (NN:[284..288] acid)))
          (ADVP-TMP-1 (-NONE-:[288..288] *T*)))))
    (,:[288..289] ,)
    (NP-SBJ (JJ:[290..294] many) (NN:[295..308] neuroblastoma)
            (NN:[309..313] cell) (NNS:[314..319] lines))
    (VP
      (VP (VBP:[320..327] undergo)
        (NP (JJ:[329..337] neuronal) (NN:[338..353] differentiation)))
      (CC:[354..357] and)
      (VP (VBP:[358..362] show)
        (NP
          (NP (DT:[363..364] a) (JJ:[365..376] significant)
              (NN:[377..385] increase))
          (PP (IN:[386..388] in)
            (NP (JJ:[389..394] human)
              (NML
                (NML
                  (NML
                    (NML (AFX:[395..400] multi) (HYPH:[400..401] -)
                         (NN:[401..405] drug))
                    (NN:[407..417] resistance))
                  (NN:[418..422] gene))
                (NML (-LRB-:[423..424] -LRB-) (NN:[424..428] MDRI)
                     (-RRB-:[428..429] -RRB-)))
              (NN:[430..440] transcript) (NNS:[441..447] levels))))))
    (.:[447..448] .)))

;sentence 5 Span:449..762
;To determine whether over-expression  of the gene may result from activation
;of its promoter by differentiating  agents, the activity of the human MDRI
;proximal promoter (MDRI pp) transfected  to 2 neuroblastoma lines treated
;with retinoic acid and forskolin was first  measured using transient
;expression assays.
;[596..600]:gene-rna:"MDRI"
;[620..624]:gene-rna:"MDRI"
;[647..660]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (S-PRP
      (NP-SBJ (-NONE-:[449..449] *))
      (VP (TO:[449..451] To)
        (VP (VB:[452..461] determine)
          (SBAR (IN:[462..469] whether)
            (S
              (NP-SBJ
                (NP (AFX:[470..474] over) (HYPH:[474..475] -)
                    (NN:[475..485] expression))
                (PP (IN:[487..489] of)
                  (NP (DT:[490..493] the) (NN:[494..498] gene))))
              (VP (MD:[499..502] may)
                (VP (VB:[503..509] result)
                  (PP-CLR (IN:[510..514] from)
                    (NP
                      (NP (NN:[515..525] activation))
                      (PP (IN:[526..528] of)
                        (NP (PRP$:[529..532] its) (NN:[533..541] promoter)))
                      (PP (IN:[542..544] by)
                        (NP (VBG:[545..560] differentiating)
                            (NNS:[562..568] agents))))))))))))
    (,:[568..569] ,)
    (NP-SBJ-1
      (NP (DT:[570..573] the) (NN:[574..582] activity))
      (PP (IN:[583..585] of)
        (NP
          (NP (DT:[586..589] the) (JJ:[590..595] human)
            (NML
              (NML (NN:[596..600] MDRI) (JJ:[601..609] proximal)
                   (NN:[610..618] promoter))
              (NML (-LRB-:[619..620] -LRB-) (NN:[620..624] MDRI)
                   (NN:[625..627] pp) (-RRB-:[627..628] -RRB-))))
          (VP (VBN:[629..640] transfected)
            (NP (-NONE-:[640..640] *))
            (PP (TO:[642..644] to)
              (NP
                (NP (CD:[645..646] 2) (NN:[647..660] neuroblastoma)
                    (NNS:[661..666] lines))
                (VP (VBN:[667..674] treated)
                  (NP (-NONE-:[674..674] *))
                  (PP (IN:[675..679] with)
                    (NP
                      (NP (JJ:[680..688] retinoic) (NN:[689..693] acid))
                      (CC:[694..697] and)
                      (NP (NN:[698..707] forskolin)))))))))))
    (VP (VBD:[708..711] was)
      (VP
        (ADVP (RB:[712..717] first))
        (VBN:[719..727] measured)
        (NP-1 (-NONE-:[727..727] *))
        (S-MNR
          (NP-SBJ (-NONE-:[727..727] *))
          (VP (VBG:[728..733] using)
            (NP (NN:[734..743] transient) (NN:[744..754] expression)
                (NNS:[755..761] assays))))))
    (.:[761..762] .)))

;sentence 6 Span:763..850
;The MDRI gene transcript levels of  these 2 lines were then measured by
;Northern blots.
;[767..771]:gene-rna:"MDRI"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[763..766] The)
        (NML (NN:[767..771] MDRI) (NN:[772..776] gene))
        (NN:[777..787] transcript) (NNS:[788..794] levels))
      (PP (IN:[795..797] of)
        (NP (DT:[799..804] these) (CD:[805..806] 2) (NNS:[807..812] lines))))
    (VP (VBD:[813..817] were)
      (ADVP (RB:[818..822] then))
      (VP (VBN:[823..831] measured)
        (NP-1 (-NONE-:[831..831] *))
        (PP-MNR (IN:[832..834] by)
          (NP (JJ:[835..843] Northern) (NNS:[844..849] blots)))))
    (.:[849..850] .)))

;sentence 7 Span:851..1118
;The results indicate that  retinoic acid and forskolin were able to activate
;the human MDRI pp in a  dose-dependent manner after transfection of the MDRI
;pp-CAT constructs in the 2  cell models tested, i.e., SK-N-SH and IGR-N-91, a
;new human neuroblastoma cell  line.
;[938..945]:gene-rna:"MDRI pp"
;[1000..1007]:gene-rna:"MDRI pp"
;[1008..1011]:gene-rna:"CAT"
;[1093..1106]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (NP-SBJ (DT:[851..854] The) (NNS:[855..862] results))
    (VP (VBP:[863..871] indicate)
      (SBAR (IN:[872..876] that)
        (S
          (NP-SBJ-1
            (NP (JJ:[878..886] retinoic) (NN:[887..891] acid))
            (CC:[892..895] and)
            (NP (NN:[896..905] forskolin)))
          (VP (VBD:[906..910] were)
            (ADJP-PRD (JJ:[911..915] able)
              (S
                (NP-SBJ-1 (-NONE-:[915..915] *))
                (VP (TO:[916..918] to)
                  (VP (VB:[919..927] activate)
                    (NP (DT:[928..931] the) (JJ:[932..937] human)
                       (NN:[938..942] MDRI) (NN:[943..945] pp))
                    (PP (IN:[946..948] in)
                      (NP (DT:[949..950] a)
                        (ADJP (NN:[952..956] dose) (HYPH:[956..957] -)
                              (JJ:[957..966] dependent))
                        (NN:[967..973] manner)))
                    (PP-TMP (IN:[974..979] after)
                      (NP
                        (NP (NN:[980..992] transfection))
                        (PP (IN:[993..995] of)
                          (NP
                            (NP (DT:[996..999] the)
                              (NML
                                (NML (NN:[1000..1004] MDRI) (NN:[1005..1007] pp))
                                (HYPH:[1007..1008] -)
                                (NML (NN:[1008..1011] CAT)))
                              (NNS:[1012..1022] constructs))
                            (PP (IN:[1023..1025] in)
                              (NP
                                (NP
                                  (NP (DT:[1026..1029] the) (CD:[1030..1031] 2)
                                      (NN:[1033..1037] cell)
                                      (NNS:[1038..1044] models))
                                  (VP (VBN:[1045..1051] tested)
                                    (NP (-NONE-:[1051..1051] *))))
                                (,:[1051..1052] ,)
                                (NP
                                  (ADVP (FW:[1053..1057] i.e.))
                                  (,:[1057..1058] ,)
                                  (NP (NN:[1059..1066] SK-N-SH))
                                  (CC:[1067..1070] and)
                                  (NP
                                    (NP (NN:[1071..1079] IGR-N-91))
                                    (,:[1079..1080] ,)
                                    (NP (DT:[1081..1082] a)
                                        (JJ:[1083..1086] new)
                                        (JJ:[1087..1092] human)
                                        (NN:[1093..1106] neuroblastoma)
                                        (NN:[1107..1111] cell)
                                        (NN:[1113..1117] line))))))))))))))))))
    (.:[1117..1118] .)))

;sentence 8 Span:1119..1276
;A significant increase in MDRI gene transcript levels was observed upon 
;treatment with differentiation inducers in SK-N-SH but not in IGR-N-91 
;neuroblasts.
;[1145..1149]:gene-rna:"MDRI"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1119..1120] A) (JJ:[1121..1132] significant)
          (NN:[1133..1141] increase))
      (PP (IN:[1142..1144] in)
        (NP
          (NML (NN:[1145..1149] MDRI) (NN:[1150..1154] gene))
          (NN:[1155..1165] transcript) (NNS:[1166..1172] levels))))
    (VP (VBD:[1173..1176] was)
      (VP
        (VP (VBN:[1177..1185] observed)
          (NP-1 (-NONE-:[1185..1185] *))
          (PP (IN:[1186..1190] upon)
            (NP
              (NP (NN:[1192..1201] treatment))
              (PP (IN:[1202..1206] with)
                (NP (NN:[1207..1222] differentiation)
                    (NNS:[1223..1231] inducers)))))
          (PP=2 (IN:[1232..1234] in)
            (NP (NN:[1235..1242] SK-N-SH)
              (NML-3 (-NONE-:[1242..1242] *P*)))))
        (CC:[1243..1246] but)
        (VP (RB:[1247..1250] not)
          (PP=2 (IN:[1251..1253] in)
            (NP (NN:[1254..1262] IGR-N-91)
              (NML-3 (NNS:[1264..1275] neuroblasts)))))))
    (.:[1275..1276] .)))

;sentence 9 Span:1277..1482
;These results suggest that the induction of the MDRI gene promoter  is
;necessary but not sufficient to lead to an increase in MDRI gene transcript 
;levels, according to the neuroblast cell line considered.
;[1325..1329]:gene-rna:"MDRI"
;[1403..1407]:gene-rna:"MDRI"
(SENT
  (S
    (NP-SBJ (DT:[1277..1282] These) (NNS:[1283..1290] results))
    (VP (VBP:[1291..1298] suggest)
      (SBAR (IN:[1299..1303] that)
        (S
          (NP-SBJ
            (NP (DT:[1304..1307] the) (NN:[1308..1317] induction))
            (PP (IN:[1318..1320] of)
              (NP (DT:[1321..1324] the)
                (NML (NN:[1325..1329] MDRI) (NN:[1330..1334] gene))
                (NN:[1335..1343] promoter))))
          (VP (VBZ:[1345..1347] is)
            (ADJP-PRD
              (ADJP (JJ:[1348..1357] necessary)
                (S-1 (-NONE-:[1357..1357] *RNR*)))
              (CONJP (CC:[1358..1361] but) (RB:[1362..1365] not))
              (ADJP (JJ:[1366..1376] sufficient)
                (S-1 (-NONE-:[1376..1376] *RNR*)))
              (S-1
                (NP-SBJ (-NONE-:[1376..1376] *))
                (VP (TO:[1377..1379] to)
                  (VP (VB:[1380..1384] lead)
                    (PP (TO:[1385..1387] to)
                      (NP
                        (NP (DT:[1388..1390] an) (NN:[1391..1399] increase))
                        (PP (IN:[1400..1402] in)
                          (NP
                            (NML (NN:[1403..1407] MDRI) (NN:[1408..1412] gene))
                            (NN:[1413..1423] transcript)
                             (NNS:[1425..1431] levels)))))))))
            (,:[1431..1432] ,)
            (PP (VBG:[1433..1442] according)
              (PP (TO:[1443..1445] to)
                (NP
                  (NP (DT:[1446..1449] the) (NN:[1450..1460] neuroblast)
                      (NN:[1461..1465] cell) (NN:[1466..1470] line))
                  (VP (VBN:[1471..1481] considered)
                    (NP (-NONE-:[1481..1481] *))))))))))
    (.:[1481..1482] .)))

;section 10 Span:1486..1530
;PMID: 8101511 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1486..1490] PMID) (::[1490..1491] :) (CD:[1492..1499] 8101511)
        (NN:[1500..1501] -LSB-) (NNP:[1501..1507] PubMed) (::[1508..1509] -)
        (NN:[1510..1517] indexed) (IN:[1518..1521] for)
        (NNP:[1522..1530] MEDLINE-RSB-)))
